SLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
SLT is a technical trading company offering testing and safety control devices for the medical technology and healthcare sectors. The company specializes in products for safety and performance verification of medical equipment and bioimaging, complemented by calibration services and training programs. Its customers include OEMs which produce medical equipment, global service providers and hospitals. Founded in 1949, SLT employs 19 people and is based in Milan, Italy.
Indutrade is an international technology and industrial business group comprising more than 200 companies across 30 countries, primarily in Europe. The group operates through five business areas: industrial and engineering; infrastructure and construction; life science; process, energy and water; and technology and systems solutions. Listed on Nasdaq Stockholm, Indutrade’s majority shareholder is the Lundberg family through its holding company Lundbergföretagen, which holds a 26.6 percent stake.
Oaklins’ team in Italy acted as the exclusive financial advisor to the shareholders of SLT.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more